Get the Stockscreener App
0.00
100.00%
-0.39
After Hours:
.39
0.39
+
Seelos Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.39
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-37.07M
P/E Ratio:
0.00
EPS:
-13.73
Net Cash Flow:
$-23.91M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-97.12%
1Y Performance:
-95.25%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.498
Seelos Therapeutics Inc Stock (SEEL) Company Profile
Name
Seelos Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare SEEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEEL
Seelos Therapeutics Inc
|
0.00 | 0 | 0 | -37.07M | -23.91M | -13.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Seelos Therapeutics Inc Stock (SEEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-27-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Jul-01-21 | Initiated | Guggenheim | Buy |
| Jun-01-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-30-21 | Initiated | B. Riley Securities | Buy |
| Nov-14-19 | Initiated | The Benchmark Company | Speculative Buy |
| May-14-19 | Initiated | ROTH Capital | Buy |
View All
Seelos Therapeutics Inc Stock (SEEL) Latest News
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V - The Manila Times
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week LowHere's Why - MSN
J&J Expands Ketamine Case With Spravato Monotherapy Indication - insights.citeline.com
SEELQ (Seelos Therapeutics) PS Ratio : (As of Jan. 06, 2025) - GuruFocus.com
Seelos Therapeutics (NASDAQ:SEEL) Stock Price Down 4.3% – Time to Sell? - Defense World
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - The Eastern Progress Online
PTC halts development of ALS drug after trial miss - The Pharma Letter
SEELQ (Seelos Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
Seelos Therapeutics files for Chapter 11 bankruptcy By Investing.com - Investing.com Canada
Seelos Therapeutics files for Chapter 11 bankruptcy - Investing.com
SEELQ (Seelos Therapeutics) Cash Flow from Investing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Operating Cash Flow per Share : $-234.50 (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Long-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Cash Flow from Financing : $7.73 Mil (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Shares Outstanding (EOP) : 0.21 Mil (As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Enterprise Value : $10.07 Mil (As of Nov. 21, 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Free Cash Flow : $-13.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) EPS (Diluted) : $-475.52 (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) EV-to-Revenue : (As of Nov. 20, 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) 14-Day RSI : 23.94 (As of Nov. 20, 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Preferred Stock : $0.00 Mil (As of Jun. 2024) - GuruFocus.com
Seelos Announces Second Postponement of its Annual Meeting of St - GuruFocus.com
SEELQ (Seelos Therapeutics) 9-Day RSI : 19.65 (As of Nov. 21, 2024) - GuruFocus.com
Biopharm Co. Seelos Files For Ch. 11 After Nasdaq Delisting - Law360
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock - Quantisnow
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split - GuruFocus.com
Seelos Announces Postponement of its Annual Meeting of Stockholders - GuruFocus.com
SEELOS THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Seelos Therapeutics announces the signing of a Material Transfer - GuruFocus.com
Seelos Announces Second Postponement of its Annual Meeting of Stockholders - StockTitan
Seelos Therapeutics (NASDAQ:SEEL) and Zoetis (NYSE:ZTS) Head-To-Head Contrast - Defense World
SEEL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Closing Bell Recap: Seelos Therapeutics Inc (SEEL) Ends at 1.28, Reflecting a -47.76 Downturn - The Dwinnex
Seelos Therapeutics Delisted From Nasdaq, Will Transition To OTC Market - Benzinga
Seelos gets Nasdaq delisting notice - MSN
SEEL stock touches 52-week low at $2.37 amid market challenges By Investing.com - Investing.com South Africa
SEEL stock touches 52-week low at $2.37 amid market challenges - Investing.com
Seelos Therapeutics Inc (SEEL) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Financial Health Check: Examining Seelos Therapeutics Inc (SEEL)’s Key Ratios - The Dwinnex
Seelos Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Seelos Therapeutics faces Nasdaq delisting over share price - Investing.com
SEEL stock touches 52-week low at $2.77 amid market challenges By Investing.com - Investing.com South Africa
SEEL stock touches 52-week low at $2.77 amid market challenges - Investing.com Australia
Was Seelos Therapeutics Inc (SEEL)’s session last reading good? - US Post News
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected - Benzinga
Seelos Therapeutics approves reverse stock split By Investing.com - Investing.com South Africa
Seelos Therapeutics approves reverse stock split - Investing.com India
Seelos Therapeutics Announces Reverse Stock Split and Adjustments - TipRanks
Seelos Therapeutics Inc Stock (SEEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.89%
0.13%
Cap:
|
Volume (24h):